{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:55:03Z","timestamp":1789584903351,"version":"build-2803163510"},"reference-count":27,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":264,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nuclear protein in testis (NUT) carcinomas are aggressive, poorly or undifferentiated cancers, generally arising from midline structures. This subtype of squamous cell carcinoma is rare and has a poor prognosis. NUT cancers are defined by NUTM1 fusions. Rearrangements of the NUTM1 gene have rarely been described in primary thyroid cancer and are mainly reported in patients \u226445 years old. NSD3::NUTM1 translocation is the most common NUTM1 fusion transcript reported in thyroid cancer. As they are very infrequent, NUTM1 fusions are not routinely sought in poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report two PDTC patients &amp;gt;65 years old with locally advanced disease and 18FDG-avid distant metastases. NSD3::NUTM1 translocation was evidenced in both patients by RNA sequencing using the next-generation sequencing panel of our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We suggest including the search for NUTM1 fusions in the RNA sequencing panel for advanced and refractory thyroid cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0100","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:51:53Z","timestamp":1758707513000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":1,"title":["<i>NSD3::NUTM1<\/i>\n                    fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5181-8182","authenticated-orcid":true,"given":"Renaud","family":"Ciappuccini","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Saguet-Rysanek","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Antoine","family":"Bompain","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Balosso","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Leman","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bardet","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2026070714011541100_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cancergencyto.2010.06.007","article-title":"NUT midline carcinoma","volume":"203","author":"French","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"2026070714011541100_bib2","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026070714011541100_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz094","article-title":"An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2026070714011541100_bib4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT carcinoma: clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol Int"},{"key":"2026070714011541100_bib5","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"2026070714011541100_bib6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3\u2013NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discov"},{"key":"2026070714011541100_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00428-021-03103-8","article-title":"NSD3-NUTM1-rearranged carcinoma of the median neck\/thyroid bed developing after recent thyroidectomy for sclerosing mucoepidermoid carcinoma with eosinophilia: report of an extraordinary case","volume":"479","author":"Agaimy","year":"2021","journal-title":"Virchows Arch"},{"key":"2026070714011541100_bib8","article-title":"Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive IGKV gene fusions: a case report with treatment implications and literature review","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"2026070714011541100_bib9","first-page":"1271","article-title":"Possible primary thyroid nuclear protein in testis carcinomas with NSD3::NUTM1 translocation revealed by RNA sequencing: a report of two cases","volume":"32","author":"Scherman","year":"2022","journal-title":"Thyroid"},{"key":"2026070714011541100_bib10","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/PAS.0000000000001967","article-title":"NUTM1 -rearranged carcinoma of the thyroid: a distinct subset of NUT carcinoma characterized by frequent NSD3 \u2013 NUTM1 fusions","volume":"46","author":"Barletta","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"2026070714011541100_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12022-021-09700-2","article-title":"Thyroid carcinoma with NSD3::NUTM1 fusion: a case with thyrocyte differentiation and colloid production","volume":"33","author":"Allison","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026070714011541100_bib12","article-title":"A rare case of NUT carcinoma of the thyroid","volume":"2","author":"Cadesky","year":"2024","journal-title":"JCEM Case Rep"},{"key":"2026070714011541100_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.22838","article-title":"Emerging entities in NUTM1-rearranged neoplasms","volume":"59","author":"McEvoy","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2026070714011541100_bib14","first-page":"304","article-title":"BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"2026070714011541100_bib15","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1101\/gad.267583.115","article-title":"The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev"},{"key":"2026070714011541100_bib16","doi-asserted-by":"crossref","first-page":"E4184","DOI":"10.1073\/pnas.1702086114","article-title":"Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma","volume":"114","author":"Alekseyenko","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070714011541100_bib17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41388-020-01625-0","article-title":"Supercharging BRD4 with NUT in carcinoma","volume":"40","author":"Eagen","year":"2021","journal-title":"Oncogene"},{"key":"2026070714011541100_bib18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/onc.2013.126","article-title":"MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma","volume":"33","author":"Grayson","year":"2014","journal-title":"Oncogene"},{"key":"2026070714011541100_bib19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/annonc\/mdw686","article-title":"Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"2026070714011541100_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jcp.2007.052902","article-title":"Demystified molecular pathology of NUT midline carcinomas","volume":"63","author":"French","year":"2010","journal-title":"J Clin Pathol"},{"key":"2026070714011541100_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","article-title":"Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody","volume":"33","author":"Haack","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2026070714011541100_bib22","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","article-title":"Report of the first international symposium on NUT carcinoma","volume":"28","author":"French","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070714011541100_bib23","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.3390\/cancers14174079","article-title":"BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1\/2a trial","volume":"14","author":"Hilton","year":"2022","journal-title":"Cancers"},{"key":"2026070714011541100_bib24","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with Birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070714011541100_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2026070714011541100_bib26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ijc.33861","article-title":"Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: results of a Phase I\/II open-label, dose escalation study","volume":"150","author":"Cousin","year":"2022","journal-title":"Int J Cancer"},{"key":"2026070714011541100_bib27","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/5\/ETJ-25-0100.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/5\/ETJ-25-0100.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0100\/507046\/etj-25-0100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0100\/507046\/etj-25-0100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:28Z","timestamp":1783447288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/5\/e250100\/75648\/NSD3-NUTM1-fusion-evidenced-on-RNA-sequencing-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0100","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"article-number":"e250100"}}